CAPLYTA ranks highest in efficacy and safety among adjunctive therapies for major depressive disorder.

A network meta-analysis comparing CAPLYTA (lumateperone) with other FDA-approved atypical antipsychotics for adjunctive treatment of major depressive disorder (MDD) found CAPLYTA superior in efficacy across four key measures and showed no significant weight gain. Presented at the 2026 NEI Spring Congress, the analysis used data from 10 clinical trials and highlighted CAPLYTA's favorable safety profile, including lower risk of akathisia and weight gain compared to other treatments. These findings offer valuable indirect comparative insights to guide treatment decisions in the absence of direct head-to-head trials, supporting CAPLYTA as an effective adjunctive option for adults with MDD who do not respond adequately to antidepressants alone.